The clinical management of schizophrenia in bipolar disorder (BD) is not straightforward and requires further research. However, the efficacy and tolerability of olanzapine (Zyprexa, Zyprexa®) is controversial. While studies suggest that olanzapine reduces the severity of schizophrenia, a meta-analysis suggested that the tolerability of olanzapine may be as low as the risk of death in individuals with BD who do not respond to olanzapine alone (,). Therefore, this study investigated the effect of olanzapine on the risk of death in the general population. Two thousand adult patients with BD with schizophrenia were treated with olanzapine (Zyprexa®, Zyprexa®) at doses of 10 mg, 20 mg and 40 mg in 1-year intervals. The primary outcome was the incidence of death during the study period. Secondary outcomes included the incidence of death, the incidence of treatment-naive death, and the incidence of death at the end of the study. The analysis was conducted using intention to treat (ITT) population. The pooled incidence of death was 12.5% (95% confidence interval [CI], 10.6%–19.7%). For the incidence of treatment-naive death, the pooled incidence of death was 10.3% (95% CI, 5.3%–14.7%). In addition, the incidence of death at the end of the study was significantly higher in patients who died in the treatment group (n = 4,ampa) than in the placebo group (n = 1,ampa). The incidence of treatment-naive death was lower in the olanzapine group (n = 1,ampa) than in the placebo group (n = 1,ampa), which was also significantly lower than that in the placebo group (n = 1,ampa). The mean age of patients with schizophrenia was 54.7±9.1 years. The incidence of death was higher in the olanzapine group (n = 12,ampa) than in the placebo group (n = 4,ampa), which was also significantly higher than that in the placebo group (n = 1,ampa). The mean length of hospitalization for bipolar I disorder was 12.4±0.5 days in the olanzapine group and 6.8±0.5 days in the placebo group. The mean time to death was 13.3±0.9 days in the olanzapine group and 11.8±0.6 days in the placebo group. The mean time to death was 13.5±0.8 days in the olanzapine group and 11.7±0.8 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). In conclusion, the clinical efficacy of olanzapine is not inferior to placebo in the treatment of schizophrenia. The safety profile of olanzapine is similar to that of placebo in the treatment of schizophrenia. The incidence of treatment-naive death was significantly higher in the olanzapine group. The incidence of treatment-related death was also significantly higher in the olanzapine group than in the placebo group. The mean duration of hospitalization for bipolar I disorder was 10.5±0.7 days in the olanzapine group and 10.2±0.9 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean time to death was 13.7±0.9 days in the olanzapine group and 11.3±0.6 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean length of hospitalization for bipolar I disorder was 12.4±0.5 days in the olanzapine group and 12.4±0.6 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean time to death was 13.5±0.8 days in the olanzapine group and 12.5±0.6 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean length of hospitalization for bipolar I disorder was 12.6±0.5 days in the olanzapine group and 12.6±0.6 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean time to death was 13.5±0.8 days in the olanzapine group and 12.6±0.6 days in the placebo group, which was significantly higher than that in the placebo group (n = 1,ampa). The mean duration of hospitalization for bipolar I disorder was 12.
The
on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist.
ZYPREXA contains the active ingredient olanzapine. ZYPREXA is used to treat patients with schizophrenia (a psychiatric disorder) or a manic or mixed episodes type of bipolar disorder.
For more information, see Section
in the full CMI.
Do not use if you have ever had an allergic reaction to olanzapine, any of the ingredients listed at the end of the CMI.
Talk to your doctor if you have any other medical conditions, take any other medicines, or are pregnant or plan to become pregnant or are breastfeeding.Some medicines may interfere with ZYPREXA and affect how it works.
Take ZYPREXA exactly as your doctor has prescribed.
Your doctor will tell you how many tablets to take, how many to take, how often to take each dose, and what to do if you forget to take a dose.
Things you should do | Remind any doctor, dentist or pharmacist you visit that you are using ZYPREXA. Remind you that you are taking this medicine. Tell your doctor if you become pregnant while taking ZYPREXA. Tell your doctor if you have ever had a seizure. Tell your doctor if you have or have had any kidney problems, a liver condition or a heart condition. Tell your doctor if you have or have had any type of allergic reaction to ZYPREXA, any other medicines you take, or any other health problems. Tell your doctor if you are using any other medicine. Do not breastfeed while taking ZYPREXA. Talk to your doctor if you are not sure if you would benefit from a special diet. See Section for a list of medicines and health problems that may affect your blood pressure or heart rate.6. Are there any side effects?Common side effects may include: headache, dizziness, feeling unstirred or restless, hot flushes, sleepiness or sleep disturbances (difficulty in sleeping), constipation, dry mouth, blurred vision, tiredness or dizziness, weight gain, weight loss, stomach pain, nausea, vomiting, stomach pain, constipation, diarrhea or stomach pain, muscle pain, cramps, weakness or weakness, pain in the arms, back or legs, numbness, pain in the hands or feet, rashes or itching, sore throat or tongue. For more information, including what to do if you have any side effects, see Section |
|---|
Zyprexa Relprevv is an oral antipsychotic medicine that is prescribed to the treatment of schizophrenia. Zyprexa Relprevv helps restore the balance of dopamine and norepinephrine in the brain and is used to treat the symptoms of schizophrenia. The medicine works by balancing the levels of these natural chemicals in the brain.
Zyprexa Relprevv belongs to a class of medicines called atypical antipsychotics. It works by correcting the balance of neurotransmitters in the brain and is used to treat several mental health conditions, such as schizophrenia. In addition, Zyprexa Relprevv helps patients who are suffering from a condition such as dementia or low levels of energy. Zyprexa Relprevv may also be used for other uses, including for purposes not listed in this medication guide.
Zyprexa Relprevv should be taken as prescribed by your doctor. Your doctor may start your treatment with a dose that will gradually increase your dose over a few days. The medicine is usually taken once or twice a day. The medicine may be given to patients who have already lost weight and are experiencing symptoms of schizophrenia.
Zyprexa Relprevv is not usually recommended for use by women unless prescribed by a doctor. It may be used for women only. If you are pregnant or breastfeeding, discuss with your doctor how Zyprexa Relprevv might affect your baby. It may be necessary to avoid alcohol when taking Zyprexa Relprevv.
Do not take Zyprexa Relprevv if you:
Zyprexa Relprevv is not suitable for children as it may be harmful to the developing baby. In the absence of adequate information, the use of Zyprexa Relprevv is strongly discouraged. It is only recommended to take Zyprexa Relprevv as directed by a doctor.
If you miss a dose of Zyprexa Relprevv, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose. Do not take a double dose to make up for a missed one.
Like all medicines, Zyprexa Relprevv can cause side effects. Some common side effects of Zyprexa Relprevv may include:
The most common side effects of Zyprexa Relprevv include:
If you experience any of these side effects or have any concerns about them, contact your doctor immediately.
It is important to keep your Zyprexa Relprevv tablets protected from external and internal parasites and bacteria. The medicine should be stored below 25°C in the refrigerator. You can also take it to avoid the risk of side effects. You should always keep your Zyprexa Relprevv at room temperature.
You should only use Zyprexa Relprevv when prescribed by a doctor. It is important to keep your Zyprexa Relprevv tablets in their original packaging and keep them away from moisture and heat. Store Zyprexa Relprevv at room temperature in a tightly closed container. Do not store Zyprexa Relprevv in the bathroom or the office setting.
Zyprexa® is an antipsychotic drug that is used to treat schizophrenia and bipolar disorder. It works by reducing the levels of certain chemicals in the brain that may contribute to the development and maintenance of bipolar disorder. Zyprexa® works by blocking the actions of certain chemicals in the brain. It is a selective serotonin reuptake inhibitor (SSRI) that helps to delay the release of serotonin from neurons and improve their function. Zyprexa® is used to treat symptoms of schizophrenia and bipolar disorder in adults and children 12 years and older. Zyprexa® is approved by the U. S. Food and Drug Administration (FDA) for the treatment of these conditions.
Zyprexa® is not suitable for use in the elderly, and older adults. It should only be used for elderly patients who have a history of weight problems or metabolic disease. It is not recommended for children and elderly patients, who are unable to swallow tablets.
Patients should be monitored for signs of side effects such as hallucinations or difficulty speaking or thinking, mood changes, and other changes in the body.
Zyprexa® is not recommended for patients with known or suspected allergies to Zyprexa®. Zyprexa® can interact with some medications. It should only be used in elderly patients who have a history of psychiatric disorders, as it may increase the risk of death or a stroke in these patients.
Zyprexa® is not indicated for use in children.
The prescribing information for this drug states that Zyprexa® is not approved for use in patients aged 65 or over who have had a history of hypersensitivity to Zyprexa® or any of its ingredients.
This article is republished from the.
Federal law restricts this drug to use by or on the order of a licensed healthcare provider. This drug may only be used in accordance with the federal law and regulations that are being followed. The information in this article is not an exhaustive guide. This article provides information about the drug and its uses, side effects, drug interactions, warnings and precautions, and drug interactions between this and other drugs. This article does not contain all possible drug interactions. The information in this article does not replace the need for medical advice. It should not be construed as a substitute for independent medical care. See your health care provider if you have any questions or concerns. If you would like to learn more about the risks and benefits of this drug, talk with your health care provider.The information in this article does not replace independent medical care.Zyprexa® is a member of a class of drugs known asantipsychotics. Antipsychotics work by balancing the levels of certain chemicals in the brain, such as dopamine and serotonin, in the brain. Antipsychotics may also affect the balance of these chemicals in the body. In some cases, these chemicals may be blocked by medications used to treat psychotic symptoms.
The FDA has approved Zyprexa® for the treatment of schizophrenia and bipolar disorder in adults. The dosage may be adjusted based on the clinical condition being treated and the patient's response to treatment. Zyprexa® is also approved for the treatment of bipolar mania or bipolar depression in adults.
Zyprexa® is not approved for the treatment of schizophrenia or bipolar disorder in children, and other psychotic symptoms may occur in the absence of a diagnosis.
Zyprexa® is not approved for the treatment of schizophrenia in adults.
A doctor may prescribe Zyprexa® for patients who are unable to swallow tablets, have a history of weight problems or metabolic disease, or who are pregnant or breastfeeding. For patients with a history of weight problems or metabolic disease, the drug may be used to treat weight gain. If a patient has a history of weight problems or metabolic disease, a doctor may prescribe Zyprexa® for these patients. The drug may be used to treat symptoms of schizophrenia in adults.
Zyprexa® is not approved for the treatment of bipolar mania or bipolar depression in children.
Stade de France Pharmacy